利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.025 秒)

    Biguanide drug-containing jelly preparation
    1.
    发明申请
    Biguanide drug-containing jelly preparation 审中-公开
    双胍药物含果冻制剂

    公开(公告)号：US20070053939A1

    公开(公告)日：2007-03-08

    申请号：US10576209

    申请日：2004-10-15

    申请人： Hideakira Yokoyama ,  Akihiko Hirata ,  Hidetoshi Hamamoto ,  Masaki Ishibashi ,  Keiko Yamasaki ,  Takeru Fujii

    发明人： Hideakira Yokoyama ,  Akihiko Hirata ,  Hidetoshi Hamamoto ,  Masaki Ishibashi ,  Keiko Yamasaki ,  Takeru Fujii

    IPC分类号： A61K31/155 ,  A61K9/00

    CPC分类号： A61K47/02 ,  A61K9/0056 ,  A61K31/155 ,  A61K47/36

    摘要： The invention provides a biguanide drug-containing jelly preparation of which discomfort upon administration is decreased by the control of its harshness or bitterness. In addition, the preparation has stability and excellent ability for releasing a drug in the digestive tract. The biguanide drug-containing jelly preparation of the invention is characterized by comprising a biguanide drug, an inorganic acid, and a water-soluble polymer. The jelly preparation of the invention is excellent in both stability and ability for releasing a drug, which are usually incompatible characters, particularly by the action of the inorganic acid.

    摘要翻译： 本发明提供了一种含双胍类药物的果冻制剂，其通过控制其粗糙度或苦味来降低给药后的不适。 另外，该制剂具有在消化道中释放药物的稳定性和极好的能力。 本发明的双胍药物凝胶制剂的特征在于包含双胍药物，无机酸和水溶性聚合物。 本发明的果冻制剂在稳定性和释放药物的能力方面都是优异的，这通常是不相容的特征，特别是通过无机酸的作用。

    Liquid matrix undergoing phase transfer in vivo and liquid oral preparations
    2.
    发明申请
    Liquid matrix undergoing phase transfer in vivo and liquid oral preparations 审中-公开
    液体基质在体内进行相转移和液体口服制剂

    公开(公告)号：US20050089577A1

    公开(公告)日：2005-04-28

    申请号：US10506512

    申请日：2003-03-03

    申请人： Hideakira Yokoyama ,  Akihiko Hirata ,  Hidetoshi Hamamoto ,  Keiko Yamasaki ,  Takeru Fujii

    发明人： Hideakira Yokoyama ,  Akihiko Hirata ,  Hidetoshi Hamamoto ,  Keiko Yamasaki ,  Takeru Fujii

    IPC分类号： A61K9/00 ,  A61K31/43 ,  A61K31/496 ,  A61K31/545 ,  A61K31/65 ,  A61K31/7048 ,  A61K47/04 ,  A61K9/14

    CPC分类号： A61K9/0095 ,  A61K31/43 ,  A61K31/496 ,  A61K31/545 ,  A61K31/65 ,  A61K31/7048

    摘要： It is intended to provide a liquid matrix for medicinal use in which medicine can be easily solubilized, dispersed or suspended and which can be easily swallowed because of being liquid, has favorable working properties in sterilization and so on and a high stability, also exhibits an effect of masking bitterness, and gels in vivo so as to control the release speed of the medicine, and liquid oral preparations using the same. Namely, a liquid matrix which is a liquid assistant for facilitating swallowing medicine characterized in comprising a water-soluble polymer gelling under acidic conditions, and the breaking stress of the gel is about 3.00×103 N/m2 or more. Liquid oral preparations have favorable slow release properties even though being a liquid.

    摘要翻译： 本发明提供一种医药用液体基质，其中药物易于溶解，分散或悬浮，并且由于液体容易吞咽，在消毒等中具有良好的加工性能和高稳定性，还表现出 掩蔽苦味的效果和体内凝胶，以控制药物的释放速度，以及使用其的液体口服制剂。 即，作为促进吞咽药物的液体助剂的液体基质，其特征在于在酸性条件下含有水溶性聚合物胶凝，凝胶的断裂应力为约3.00×10 3 N / SUP> 2以上。 液体口服制剂即使是液体也具有良好的缓释特性。

    External preparation for wounds
    3.
    发明授权
    External preparation for wounds 失效
    伤口的外部准备

    公开(公告)号：US08323693B2

    公开(公告)日：2012-12-04

    申请号：US10507522

    申请日：2003-03-12

    申请人： Hidetoshi Hamamoto ,  Keiko Yamasaki ,  Hideakira Yokoyama ,  Akihiko Hirata ,  Takeru Fujii

    发明人： Hidetoshi Hamamoto ,  Keiko Yamasaki ,  Hideakira Yokoyama ,  Akihiko Hirata ,  Takeru Fujii

    IPC分类号： A61K9/14

    CPC分类号： A61L26/008 ,  A61L15/60 ,  A61L26/0014 ,  A61L26/0066 ,  A61L2300/106 ,  A61L2300/404 ,  C08L33/02

    摘要： There is provided an external preparation for wounds which has novel usability in treating skin damages accompanied by a large amount of exudation such as bedsores, skin ulcers, and burns, and yet has such advantages as observed in conventional medicines having been employed in treating these wounds. The external preparation for wounds comprises a water-soluble polymer and a crosslinking agent, and has powdery/granular or ointment form. After absorbing an exudation, the preparation undergoes phase transition from a sol to a gel by the action of ingredient of the preparation, and thus exhibits actions of adsorbing and eliminating necrotic tissues, and protecting the wounded parts. Subsequently, it can continuously absorb the exudation. After being used, it can be easily separated substantially as a mass, thereby exhibiting high therapeutic effects and usability.

    摘要翻译： 本发明提供了一种伤口外用制剂，其在治疗伴有大量渗出物如褥疮，皮肤溃疡和烧伤的皮肤损伤方面具有新颖的可用性，但具有在用于治疗这些伤口的常规药物中观察到的优点 。 用于伤口的外用制剂包括水溶性聚合物和交联剂，并且具有粉末/颗粒或软膏形式。 在吸收渗出物后，制剂通过制剂成分的作用从溶胶到凝胶发生相变，从而显示出吸附和消除坏死组织并保护受伤部位的作用。 随后，它可以连续吸收渗出物。 使用后，可以容易地分散为质量，从而表现出高的治疗效果和可用性。

    External preparation for wounds
    4.
    发明申请
    External preparation for wounds 失效
    伤口的外部准备

    公开(公告)号：US20050118269A1

    公开(公告)日：2005-06-02

    申请号：US10507522

    申请日：2003-03-12

    申请人： Hidetoshi Hamamoto ,  Keiko Yamasaki ,  Hideakira Yokoyama ,  Akihiro Hirata ,  Takeru Fujii

    发明人： Hidetoshi Hamamoto ,  Keiko Yamasaki ,  Hideakira Yokoyama ,  Akihiro Hirata ,  Takeru Fujii

    IPC分类号： A61L15/60 ,  A61L26/00 ,  A61K9/14

    CPC分类号： A61L26/008 ,  A61L15/60 ,  A61L26/0014 ,  A61L26/0066 ,  A61L2300/106 ,  A61L2300/404 ,  C08L33/02

    摘要： There is provided an external preparation for wounds which has novel usability in treating skin damages accompanied by a large amount of exudation such as bedsores, skin ulcers, and burns, and yet has such advantages as observed in conventional medicines having been employed in treating these wounds. The external preparation for wounds comprises a water-soluble polymer and a crosslinking agent, and has powdery/granular or ointment form. After absorbing an exudation, the preparation undergoes phase transition from a sol to a gel by the action of ingredient of the preparation, and thus exhibits actions of adsorbing and eliminating necrotic tissues, and protecting the wounded parts. Subsequently, it can continuously absorb the exudation. After being used, it can be easily separated substantially as a mass, thereby exhibiting high therapeutic effects and usability.

    摘要翻译： 本发明提供了一种伤口外用制剂，其在治疗伴有大量渗出物如褥疮，皮肤溃疡和烧伤的皮肤损伤方面具有新颖的可用性，但具有在用于治疗这些伤口的常规药物中观察到的优点 。 用于伤口的外用制剂包括水溶性聚合物和交联剂，并且具有粉末/颗粒或软膏形式。 在吸收渗出物后，制剂通过制剂成分的作用从溶胶到凝胶发生相变，从而显示出吸附和消除坏死组织并保护受伤部位的作用。 随后，它可以连续吸收渗出物。 使用后，可以容易地分散为质量，从而表现出高的治疗效果和可用性。

    Peptide having an affinity for gp120
    5.
    发明授权
    Peptide having an affinity for gp120 失效
    对gp120具有亲和力的肽

    公开(公告)号：US06827939B2

    公开(公告)日：2004-12-07

    申请号：US09757655

    申请日：2001-01-11

    申请人： Takeru Fujii ,  Hideakira Yokoyama ,  Hidetoshi Hamamoto

    发明人： Takeru Fujii ,  Hideakira Yokoyama ,  Hidetoshi Hamamoto

    IPC分类号： A61K3912

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K14/005 ,  C12N2740/16122

    摘要： The peptide in this invention is a peptide having affinity to gp120 represented by H-A1-A2-A3-A4-A5-R (SEQ ID No. 1)  Formula (1) (in the formula, H means hydrogen, A1 is aspartic acid, lysine, valine, glutamic acid, glycine, asparagine, or tyrosine residue, A2 is valine, aspartic acid, tryptophan, lysine, phenylalanine, isoleucine, leucine, or tyrosine residue, A3 is lysine, valine, aspartic acid, arginine, alanine, or tryptophan residue, A4 is alanine, tryptophan, or glycine residue, A5 is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tryptophan, proline, or tyrosine residue, R is OH derived from carboxyl group or NH2 derived from acid amide group).

    摘要翻译： 本发明中的肽是对gp120具有亲和性的肽（式中，H表示氢，A1为天冬氨酸，赖氨酸，缬氨酸，谷氨酸，甘氨酸，天冬酰胺或酪氨酸残基，A2为缬氨酸，天冬氨酸， A3是赖氨酸，缬氨酸，天冬氨酸，精氨酸，丙氨酸或色氨酸残基，A4是丙氨酸，色氨酸或甘氨酸残基，A5是甘氨酸，丙氨酸，缬氨酸，亮氨酸 ，异亮氨酸，丝氨酸，苏氨酸，甲硫氨酸，天冬酰胺，谷氨酰胺，组氨酸，赖氨酸，精氨酸，苯丙氨酸，色氨酸，脯氨酸或酪氨酸残基，R是衍生自羧基的OH或衍生自酰胺基的NH2）。

    Peptide having an affinity for gp120
    6.
    发明授权
    Peptide having an affinity for gp120 失效
    对gp120具有亲和力的肽

    公开(公告)号：US07291337B2

    公开(公告)日：2007-11-06

    申请号：US10909310

    申请日：2004-08-03

    申请人： Takeru Fujii ,  Hideakira Yokoyama ,  Hidetoshi Hamamoto

    发明人： Takeru Fujii ,  Hideakira Yokoyama ,  Hidetoshi Hamamoto

    IPC分类号： A61K39/15

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K14/005 ,  C12N2740/16122

    摘要： The peptide in this invention is a peptide having affinity to gp120 represented by Formula (1): H-A1-A2-A3-A4-A5-R(SEQ ID No. 1) (in the formula, H means hydrogen, A1 is aspartic acid, lysine, valine, glutamic acid, glycine, asparagine, or tyrosine residue, A2 is valine, aspartic acid, tryptophan, lysine, phenylalanine, isoleucine, leucine, or tyrosine residue, A3 is lysine, valine, aspartic acid, arginine, alanine, or tryptophan residue, A4 is alanine, tryptophan, or glycine residue, A5 is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tryptophan, proline, or tyrosine residue, R is OH derived from carboxyl group or NH2 derived from acid amide group). The above peptide has an affinity to gp120 of the HIV envelope protein and is superior in stability.

    摘要翻译： 本发明中的肽是对由式（1）表示的gp120具有亲和性的肽：H-A1-A2-A3-A4-A5-R（SEQ ID No.1）（式中，H表示氢，A1为 天冬氨酸，赖氨酸，缬氨酸，谷氨酸，甘氨酸，天冬酰胺或酪氨酸残基，A2是缬氨酸，天冬氨酸，色氨酸，赖氨酸，苯丙氨酸，异亮氨酸，亮氨酸或酪氨酸残基，A3是赖氨酸，缬氨酸，天冬氨酸，精氨酸， 丙氨酸或色氨酸残基，A4是丙氨酸，色氨酸或甘氨酸残基，A5是甘氨酸，丙氨酸，缬氨酸，亮氨酸，异亮氨酸，丝氨酸，苏氨酸，甲硫氨酸，天冬酰胺，谷氨酰胺，组氨酸，赖氨酸，精氨酸，苯丙氨酸，色氨酸， 或酪氨酸残基，R为衍生自酰胺基团的羧基或NH 2的OH）。 上述肽对HIV包膜蛋白的gp120具有亲和力，并且稳定性优异。

    Peptide having an affinity for gp120
    7.
    发明申请
    Peptide having an affinity for gp120 失效
    对gp120具有亲和力的肽

    公开(公告)号：US20050004040A1

    公开(公告)日：2005-01-06

    申请号：US10909310

    申请日：2004-08-03

    申请人： Takeru Fujii ,  Hideakira Yokoyama ,  Hidetoshi Hamamoto

    发明人： Takeru Fujii ,  Hideakira Yokoyama ,  Hidetoshi Hamamoto

    IPC分类号： A61K39/12 ,  A61K38/00 ,  A61P31/18 ,  C07K7/00 ,  C07K7/06 ,  C07K14/16 ,  G01N33/569 ,  A61K38/08

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K14/005 ,  C12N2740/16122

    摘要： The peptide in this invention is a peptide having affinity to gp120 represented by Formula (1): H-A1-A2-A3-A4-A5-R (in the formula, H means hydrogen, A1 is aspartic acid, lysine, valine, glutamic acid, glycine, asparagine, or tyrosine residue, A2 is valine, aspartic acid, tryptophan, lysine, phenylalanine, isoleucine, leucine, or tyrosine residue, A3 is lysine, valine, aspartic acid, arginine, alanine, or tryptophan residue, A4 is alanine, tryptophan, or glycine residue, A5 is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tryptophan, proline, or tyrosine residue, R is OH derived from carboxyl group or NH2 derived from acid amide group). The above peptide has an affinity to gp120 of the HIV envelope protein and is superior in stability.

    摘要翻译： 本发明的肽是与式（1）表示的gp120具有亲和性的肽：H-A1-A2-A3-A4-A5-R（式中，H表示氢，A1为天冬氨酸，赖氨酸，缬氨酸， 谷氨酸，甘氨酸，天冬酰胺或酪氨酸残基，A2是缬氨酸，天冬氨酸，色氨酸，赖氨酸，苯丙氨酸，异亮氨酸，亮氨酸或酪氨酸残基，A3是赖氨酸，缬氨酸，天冬氨酸，精氨酸，丙氨酸或色氨酸残基，A4 是丙氨酸，色氨酸或甘氨酸残基，A5是甘氨酸，丙氨酸，缬氨酸，亮氨酸，异亮氨酸，丝氨酸，苏氨酸，甲硫氨酸，天冬酰胺，谷氨酰胺，组氨酸，赖氨酸，精氨酸，苯丙氨酸，色氨酸，脯氨酸或酪氨酸残基， 衍生自羧基或衍生自酰胺基团的NH 2）。 上述肽对HIV包膜蛋白的gp120具有亲和力，并且稳定性优异。

    COMPOSITE PRODUCT OF LOW-SOLUBILITY DRUG AND SURFACTANT, AND PROCESS FOR PRODUCTION THEREOF
    9.
    发明申请
    COMPOSITE PRODUCT OF LOW-SOLUBILITY DRUG AND SURFACTANT, AND PROCESS FOR PRODUCTION THEREOF 审中-公开
    低溶解性药物和表面活性剂的复合产品及其生产方法

    公开(公告)号：US20100298447A1

    公开(公告)日：2010-11-25

    申请号：US12740590

    申请日：2008-10-29

    申请人： Takeru Fujii ,  Eiji Hayakawa ,  Akihiko Hirata

    发明人： Takeru Fujii ,  Eiji Hayakawa ,  Akihiko Hirata

    IPC分类号： A61K47/44 ,  A61P31/12 ,  A61P19/02

    CPC分类号： A61K9/107 ,  A61K9/145

    摘要： This invention is intended to improve the solubility and permeability of low-solubility drugs, including drugs hardly soluble in water, classified as Class 2 or 4 in accordance with BCS by modifying such drugs into S/W, S/O, or S/O/W preparations. The S/W, S/O, or S/O/W preparations of low-solubility drugs of this invention are prepared by a method for preparing a composite of a low-solubility drug and surfactant by introducing air or nonflammable gas into the gas phase in the upper portion of a liquid level of the dispersion, dissolution, and emulsification tanks, respectively, at a pressure of 1 to 10 atm.

    摘要翻译： 本发明旨在通过将这些药物改性成S / W，S / O或S / O来改善低溶解性药物（包括难溶于水的溶解性和渗透性），按照BCS分类为2类或4类 / W准备。 本发明的低溶解度药物的S / W，S / O或S / O / W制剂是通过将空气或不可燃气体引入气体中制备低溶解度药物和表面活性剂的复合物的方法制备的 分别在分散体，溶解和乳化罐的液面的上部相分别以1至10个大气压的压力。